Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre …
Background Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1
receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients …
receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients …
[引用][C] Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre …
T Heise, A Mari, JH DeVries, S Urva, J Li… - The Lancet Diabetes & …, 2022 - cir.nii.ac.jp
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function
and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind …
and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind …
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre …
T Heise, A Mari, JH DeVries, S Urva, J Li… - The Lancet Diabetes & …, 2022 - Elsevier
Background Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1
receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients …
receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients …
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre …
T Heise, A Mari, JH DeVries… - Lancet …, 2022 - researchinformation.amsterdamumc …
Background: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1
receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients …
receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients …
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre …
T Heise, A Mari, JH DeVries, S Urva… - … lancet. Diabetes & …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1
receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients …
receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients …
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre …
T Heise, A Mari, JH DeVries, S Urva, J Li… - The lancet. Diabetes …, 2022 - europepmc.org
Background Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1
receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients …
receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients …